KNSA - Kiniksa Pharmaceuticals, Ltd.
Kiniksa Pharmaceuticals, Ltd. , a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
As of May 15, 2026: spot at $56.59, ATM IV 46.0%, max pain $45.00, net GEX $113.8K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $4.44B
- P/E Ratio
- 61.92
- Beta
- 0.17
- 52-Week Range
- 24.85-59.87
- CEO
- Sanj K. Patel
- Employees
- 315
- IPO Date
- May 25, 2018
- Exchange
- NASDAQ
What KNSA Looks Like to Options Traders Today
IV rank of 10.1% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); positive net gamma exposure ($113.8K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (0.125) prices calls richer than puts, often reflecting upside speculation or squeeze risk.
What This Page Covers
The KNSA overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked KNSA overview questions
- What is KNSA?
- KNSA is the ticker symbol for Kiniksa Pharmaceuticals, Ltd., a listed security. Kiniksa Pharmaceuticals, Ltd. , a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Listed on NASDAQ. KNSA is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the KNSA options snapshot look like today?
- As of May 15, 2026, the KNSA options snapshot shows spot at $56.59, ATM IV 46.0%, IV rank 10.1%, max pain $45.00, net GEX $113.8K, expected move 13.19%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are KNSA's key statistics?
- Kiniksa Pharmaceuticals, Ltd. (KNSA) carries a market capitalization of $4.44B, trailing P/E ratio of 61.92, beta of 0.17 relative to the broader market, 52-week range of 24.85-59.87. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does KNSA belong to?
- Kiniksa Pharmaceuticals, Ltd. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare KNSA's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the KNSA data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).